Predictive Oncology (POAI) Short-Term Debt to Capital

This daily price chart for Predictive Oncology (POAI) reflects the dynamics of a company developing Biopick software for oncology therapy analysis, where server-based calculations ensure high profitability. Simultaneously, the business is implementing "green" disposal standards and reducing the energy costs of its IT infrastructure. However, the indicator stands at 0.00, which, coupled with persistent losses and the slow adoption of technologies by pharma behemoths, creates financial risks.

For an investor assessing the market status of Predictive Oncology (POAI), the balance between debt capital and equity value is critical. By analyzing the short-term debt-to-equity ratio, you determine the proportion of liabilities with a term exceeding one year relative to equity, which allows for an assessment of the risk of shareholder dilution when scaling AI services for pharmaceutical companies and helps prevent potential cash flow gaps.